ZNTL
ZNTL clinical trials: Zentalis Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Zentalis Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 12
- As lead sponsor
- 4
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ZNTL on the catalyst calendar · ZNTL registry changes
- Primary completion May 31, 2028Sponsor estimatePhase 3NCT07546500A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian...K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian CancerRecruitingZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 1NCT04516447A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Solid TumorRecruitingZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05128825A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2023ActualPhase 1NCT04833582A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · OsteosarcomaCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2025ActualPhase 1/Phase 2NCT05198804A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian CancerCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 22, 2025ActualPhase 2NCT04814108A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Uterine Serous CarcinomaCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2025ActualPhase 1NCT04158336A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Solid TumorCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2024ActualPhase 1NCT05743036ZN-c3 in Adult Participants With Metastatic Colorectal CancerK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Metastatic Colorectal CancerTerminatedZNTLLeadPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2, 2024ActualPhase 1/Phase 2NCT05682170Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · Acute Myeloid Leukemia (AML)TerminatedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 14, 2024ActualPhase 1/Phase 2NCT05199337Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · AmyloidosisCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2021ActualPhase 1NCT04854174A Food Effect Study of ZN-d5 in Healthy Female VolunteersK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · Healthy VolunteersCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2023ActualPhase 1NCT04500587Phase 1 First in Human Study of ZN-d5 as a Single AgentK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · Acute Myeloid LeukemiaCompletedZNTLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 6, 2025ActualPhase 2NCT06015659ZN-c3 + Gemcitabine in Pancreatic CancerBrandon Huffman, MD · Advanced Pancreatic AdenocarcinomaTerminatedZNTLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2026ActualPhase 1NCT06351332ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCFilipa Lynce, MD · Breast CancerTerminatedZNTLCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 2NCT06369155Azenosertib in Uterine Serous Carcinoma: Biomarker StudyJoyce Liu, MD · Uterine Serous CarcinomaRecruitingZNTLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 1NCT05431582Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid TumorsM.D. Anderson Cancer Center · TumorsWithdrawnZNTLCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner